Epiomic Epidemiology Series: Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026
|出版商||Black Swan Analysis||商品編碼||371702|
|出版日期||內容資訊||英文 36 Pages
|α1抗胰蛋白酶缺乏症:全球9個國家的市場預測 Epiomic Epidemiology Series: Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026|
|出版日期: 2016年09月01日||內容資訊: 英文 36 Pages||
本報告提供全球主要9個國家 (美國、法國、德國、義大利、西班牙、英國、巴西、日本、印度) 的α1抗胰蛋白酶缺乏症 (AATD) 治療的市場相關分析，各國的AATD的患病人數的變化和未來預測 (今後10年份)，男女、各年齡層 (5歲分級) 及各重症度詳細趨勢，主要的併發症 (硬化，COPD (慢性阻塞性肺病)，肺癌症，氣喘，脂膜炎，全身性血管炎等)的罹患情形，主要的風險要素，預後的差異 (各地區、各民族等)，現在、未來的主要的治療方法，診斷、治療的實施情形等調查評估。
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alpha-1 Anti-Trypsin in 9 Major Markets
Alpha-1 Anti-Trypsin (AAT) is an enzyme belonging to the serpin super family, and is also referred to as alpha-1 proteinase inhibitor (A1PI) because it inhibits a wide variety of proteases. AAT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase protein. In its absence (such as in alpha 1-anti-trypsin deficiency), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs. This results in respiratory complications such as COPD (chronic obstructive pulmonary disease) in adults and cirrhosis of the liver in adults or children.
Alpha-1 Anti-Trypsin deficiency (AATD) is an inherited, rare condition that causes a complete or partial reduction in activity of Alpha-1 Anti-Trypsin (AAT) in the blood and lungs which leads to the deposit of excessive abnormal A1AT protein in liver cells.
This report provides the current prevalent population for Alpha-1 Anti-Trypsin across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Alpha-1 Anti-Trypsin have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.